Docket No.: 0020-5490PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Patent Application of: hi FUJIWARA et al.	
Application No.: 10/582,174		Confirmation No.: 8923
Filed: June 8, 2006		Art Unit: 1612
For:	A MEDICAMENT-CONTAINING PARTICLE AND A SOLID PREPARATION CONTAINING THE PARTICLE	Examiner; G. G. Huang
	INFORMATION DISCLOSURE	E STATEMENT
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		August 29, 2011
Sir:		
	Applicants hereby submit an Information Disclos	sure Statement for consideration by the
Exan	iner,	
I.	LIST OF PATENTS, PUBLICATIONS OR OTH	ER INFORMATION
	The patents, publications, or other information su	bmitted for consideration by the Office
are li	sted on the PTO-SB08.	
II.	COPIES	
\boxtimes	a. Copies of cited U.S. patents and patent app	dication publications are not included.
	b. REFERENCES PREVIOUSLY CITED mation not provided can be found in one or more or relied upon for an earlier filing date under 35 U.S.C. U.S. Application No. and U.S. Filing Date	of the following applications which has

Application No.; 10/582,174 Docket No.; 0020-5490PUS1

III. releva follow	CONCISE EXPLANATION OF THE RELEVANCE a. NON-ENGLISH LANGUAGE DOCUMENTS: A concise explanation of the nee of all non-English language patents, publications, or other information listed is as s:	
	b. ENGLISH LANGUAGE SEARCH REPORT OR FOREIGN PATENT OFFICE MUNICATION: An English language version of the search report or Foreign Patent communication that indicates the degree of relevance is attached.	
6,368,	c. OTHER: A Korean Office Action in connection with the corresponding Korean ation was issued on July 15, 2011. This Korean Office Action cites both U.S. Patent No. 625 and U.S. Patent No. 6,235,947. U.S. Patent No. 6,368,625 was previous cited and we provide additional information regarding U.S. Patent No. 6,235,947 in the attached SB08	
IV.	STATEMENT UNDER 37 C.F.R. § 1.97(e) The undersigned hereby states that:	
a. Each item of information contained in the IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than 30 days prior to the filing of this IDS. This statement does not relate to English language counterparts not listed in a communication from the foreign patent office. Such English language counterparts are provided to aid the Examiner's consideration of non-English items first cited in the communication from the foreign patent office; or		
hree	b. Each item of information contained in the IDS was first cited in any anication from a foreign patent office in a counterpart foreign application not more than months prior to the filing of this IDS. This statement does not relate to English language reparts not listed in a communication from the foreign patent office. Such English	

Application No.: 10/582,174 Docket No.: 0020-5490PUS1

language counterparts are provided to aid the Examiner's consideration of non-English items first cited in the communication from the foreign patent office; or

C. No item of information contained in the IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

d. Some of the items of information in the IDS were cited in a communication from a foreign patent office. Such items were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this IDS. This statement does not relate to English language counterparts not listed in a communication from the foreign patent office. Such English language counterparts are provided to aid the Examiner's consideration of non-English items first cited in the communication from the foreign patent office. As to the remaining items of information, to the knowledge of the person signing the certification after making reasonable inquiry, such remaining items were not known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filling of this statement.

V. FEES

- a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application or Request for Continued Examination. No fee is required.
- b. This Information Disclosure Statement is being filed within three months of the filing date of an application. No fee is required.
- C. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits. No fee is required. If a first Office Action on the merits has issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) above. If no statement has been made, charge our deposit account for the required fee.

If the Examiner has any questions concerning this IDS, please contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the USPTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

Dated: August 29, 2011

Respectfully submitted,

Mark J. Nuell, Ph.D.

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive, Suite 260

San Diego, California 92130

(703) 205-8000 Attorney for Applicant

Attachment:

PTO/SB/08